We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Cell-Specific Bioorthogonal Tagging of Glycoproteins Developed

By LabMedica International staff writers
Posted on 31 Oct 2022
Print article
Image: Development of an artificial biosynthetic pathway for chemically tagged UDP-GalNAc/GlcNAc analogues (Photo courtesy of Benjamin Schumann, PhD)
Image: Development of an artificial biosynthetic pathway for chemically tagged UDP-GalNAc/GlcNAc analogues (Photo courtesy of Benjamin Schumann, PhD)

Altered glycoprotein expression is an undisputed corollary of cancer development. Understanding these alterations is paramount but hampered by limitations underlying cellular model systems. For instance, the intricate interactions between tumor and host cannot be adequately recapitulated in monoculture of tumor-derived cell lines.

Cancer is a multifactorial disease consisting of an interplay between host and tumor. Posttranslational modifications (PTMs) heavily impact the plasticity of the proteome. Glycosylation is the most complex and most abundant PTM, but challenging to probe due to the non-templated nature of glycan biosynthesis.

Chemists and Biochemists at the Imperial College London (London, UK) have developed a new method to study the proteins released by cells, which could lead to the development of new tools to track diseases including cancer. Their method identifies proteins released by a specific type of cell, even if the cells are in a complex environment with many different cell types. The method is called Bio-Orthogonal Cell line-specific Tagging of Glycoproteins (BOCTAG).

The method uses bioorthogonal chemistry or click chemistry. The chemical tag is selected so that it "clicks" with another molecule that helps the scientists isolate the desired proteins or add a fluorescent tag to them. The investigators showed that BOCTAG worked in cell cultures with multiple cell lines and in mice, where they successfully tagged proteins from specific cancer cells. This method could also be used in fields such as immunology, infectious diseases, and to better understand disease biology, particularly how tumor cells change as a result of complex interactions in the body.

Cells are equipped by transfection with an artificial biosynthetic pathway that transforms bioorthogonally tagged sugars into the corresponding nucleotide-sugars. Only transfected cells incorporate bioorthogonal tags into glycoproteins in the presence of non-transfected cells. The team employed BOCTAG as an imaging technique and to annotate cell-specific glycosylation sites in mass spectrometry-glycoproteomics using Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) equipped with a ACQUITY UPLC BEH Glycan (Waters Corporation, Milford, MA, USA). They demonstrated application in co-culture and mouse models, allowing for profiling of the glycoproteome as an important modulator of cellular function. The study was published on October 25 2022 in the journal Nature Communications.

Related Links:
Imperial College London
Waters Corporation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The utilization of liquid biopsies in cancer research is a rapidly developing field (Photo courtesy of Lightspring/Shutterstock)

Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis

B-cell lymphoma is the predominant form of cancer affecting the lymphatic system, with about 30% of patients with aggressive forms of this disease experiencing relapse. Currently, the disease’s risk assessment... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.